Creative Medical Technology (CELZ)
Market Price (2/1/2026): $2.02 | Market Cap: $5.2 MilSector: Health Care | Industry: Biotechnology
Creative Medical Technology (CELZ)
Market Price (2/1/2026): $2.02Market Cap: $5.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -103% | Weak multi-year price returns2Y Excs Rtn is -95%, 3Y Excs Rtn is -134% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -101379% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -39% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Expensive valuation multiplesP/SPrice/Sales ratio is 869x |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -45%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -61% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 211% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -97807%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -97807% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -118% | ||
| High stock price volatilityVol 12M is 118% | ||
| Key risksCELZ key risks include [1] a heavy dependency on the success of its key clinical trials like ADAPT and CREATE-1, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -103% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -39% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -95%, 3Y Excs Rtn is -134% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -101379% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 869x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -45%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -61% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 211% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -97807%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -97807% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -118% |
| High stock price volatilityVol 12M is 118% |
| Key risksCELZ key risks include [1] a heavy dependency on the success of its key clinical trials like ADAPT and CREATE-1, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Dilution from Warrant Exercises and Shelf Registration. Creative Medical Technology Holdings announced agreements for the exercise of warrants for $4.2 million in gross proceeds on October 29, 2025. This event was cited as a factor leading to a significant stock movement, and subsequent filings indicated dilution concerns. Furthermore, an S-3 shelf registration, effective November 21, 2025, registered 2,790,340 shares for resale upon warrant exercise, suggesting that potential secondary sales by existing holders could exert downward pressure on the share price by increasing market supply.
2. Persistent Bearish Technical Trends and Market Sentiment. Analysis as of late January 2026 indicated a strong bearish trend for CELZ. The stock was described as being in a "very wide and falling trend in the short term," with technical indicators, such as the SMA_20 being below the SMA_60, signaling a bearish outlook. This existing downtrend, which some sources noted had been ongoing since late 2015, contributed to negative investor sentiment, making the stock susceptible to further declines.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.3% change in CELZ stock from 10/31/2025 to 2/1/2026 was primarily driven by a -36.3% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.17 | 2.02 | -36.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 1,363.4 | 868.8 | -36.3% |
| Shares Outstanding (Mil) | 3 | 3 | 0.0% |
| Cumulative Contribution | -36.3% |
Market Drivers
10/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| CELZ | -36.3% | |
| Market (SPY) | 1.5% | 21.2% |
| Sector (XLV) | 7.3% | 10.5% |
Fundamental Drivers
The -27.3% change in CELZ stock from 7/31/2025 to 2/1/2026 was primarily driven by a -57.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.78 | 2.02 | -27.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -57.1% |
| P/S Multiple | 393.3 | 868.8 | 120.9% |
| Shares Outstanding (Mil) | 2 | 3 | -23.2% |
| Cumulative Contribution | -27.3% |
Market Drivers
7/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| CELZ | -27.3% | |
| Market (SPY) | 9.8% | 20.6% |
| Sector (XLV) | 19.2% | 3.3% |
Fundamental Drivers
The -35.5% change in CELZ stock from 1/31/2025 to 2/1/2026 was primarily driven by a -46.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.13 | 2.02 | -35.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -45.5% |
| P/S Multiple | 396.2 | 868.8 | 119.3% |
| Shares Outstanding (Mil) | 1 | 3 | -46.0% |
| Cumulative Contribution | -35.5% |
Market Drivers
1/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| CELZ | -35.5% | |
| Market (SPY) | 16.0% | 16.0% |
| Sector (XLV) | 6.8% | 8.5% |
Fundamental Drivers
The -62.2% change in CELZ stock from 1/31/2023 to 2/1/2026 was primarily driven by a -95.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.35 | 2.02 | -62.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -95.6% |
| P/S Multiple | 54.6 | 868.8 | 1490.1% |
| Shares Outstanding (Mil) | 1 | 3 | -45.5% |
| Cumulative Contribution | -62.2% |
Market Drivers
1/31/2023 to 2/1/2026| Return | Correlation | |
|---|---|---|
| CELZ | -62.2% | |
| Market (SPY) | 76.6% | 9.1% |
| Sector (XLV) | 21.4% | 7.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CELZ Return | 31471% | -83% | 21% | -50% | -15% | 8% | 2914% |
| Peers Return | -23% | -19% | 67% | -5% | -1% | -8% | -10% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| CELZ Win Rate | 8% | 8% | 58% | 25% | 58% | 100% | |
| Peers Win Rate | 47% | 52% | 52% | 50% | 50% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| CELZ Max Drawdown | 0% | -84% | -2% | -57% | -22% | -7% | |
| Peers Max Drawdown | -36% | -42% | -17% | -25% | -35% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ORGO, MDXG, SRPT, CRSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/30/2026 (YTD)
How Low Can It Go
| Event | CELZ | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -92.4% | -25.4% |
| % Gain to Breakeven | 1209.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -90.2% | -33.9% |
| % Gain to Breakeven | 924.4% | 51.3% |
| Time to Breakeven | 613 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.0% | -19.8% |
| % Gain to Breakeven | 5000.0% | 24.7% |
| Time to Breakeven | 70 days | 120 days |
Compare to VRTX, ORGO, MDXG, SRPT, CRSP
In The Past
Creative Medical Technology's stock fell -92.4% during the 2022 Inflation Shock from a high on 3/28/2022. A -92.4% loss requires a 1209.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Creative Medical Technology (CELZ)
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Creative Medical Technology (CELZ):
- Like a **Vertex Pharmaceuticals** focused on stem cell and regenerative medicine.
- Like a **CRISPR Therapeutics** for biologic and stem cell-based therapies.
- Like an **early-stage Amgen** developing innovative stem cell and biologic treatments.
AI Analysis | Feedback
- Allogeneic Stem Cell Therapies: Therapeutic products derived from donor stem cells targeting a range of conditions including neurodegenerative, metabolic, and inflammatory diseases.
- Exosome Therapeutics: Products utilizing exosomes, which are cell-free components derived from stem cells, for regenerative and immunomodulatory applications.
- Point-of-Care Stem Cell Processing Devices: Medical devices designed for the rapid isolation and preparation of a patient's own stem cells for immediate therapeutic administration.
AI Analysis | Feedback
Creative Medical Technology (symbol: CELZ) is a clinical-stage biotechnology company focused on the development of regenerative cell-based therapeutics. As a development-stage company, CELZ is primarily engaged in research and development and managing clinical trials for its various therapeutic candidates.
Currently, CELZ does not have major commercial customers because its product candidates are still in various stages of clinical development and have not yet received regulatory approval for commercial sale. Therefore, the company does not generate significant revenue from product sales to either other companies or individuals.
In the future, should their product candidates receive regulatory approval, their business model would likely involve:
- Selling or licensing their developed therapies to larger pharmaceutical companies (B2B model).
- Potentially selling directly to specialized medical institutions (e.g., hospitals, clinics) that administer advanced cell therapies (B2B model).
However, at this time, there are no identifiable major customers to list.
AI Analysis | Feedback
nullAI Analysis | Feedback
Timothy Warbington, CEO & Co-Founder
Timothy Warbington is an accomplished entrepreneur and healthcare executive, best known as the founder and CEO of Creative Medical Technology Holdings (NASDAQ: CELZ). He has over 12 years of experience in the healthcare industry and is recognized as an innovator and leader in regenerative medicine. Warbington earned a Bachelor's degree in Accounting from Arizona State University in 1984. For over two decades, he was a principal of a leading agriculture company, owning and operating a multi-million dollar national agricultural (produce) and finance company from 1993 to 2007. In 2006, he began investing in early-stage biotech companies, which led to consulting roles with Boards of Directors and Executives in companies where he held a position, contributing to increased valuations and successful exits. Warbington founded Creative Medical in 2011 to revolutionize regenerative medicine and has served as the company's CEO and President during various periods, including his current tenure since February 2016.
Donald Dickerson, Chief Financial Officer
Donald Dickerson serves as the Chief Financial Officer and Senior Vice-President and Director of Creative Medical Technology Holdings. He was mentioned as the CFO during an investor webinar on October 1, 2024. As of November 3, 2023, he was 58 years old.
Courtney Bartlett, Director of Clinical Development
Courtney Bartlett holds the position of Director of Clinical Development at Creative Medical Technology Holdings.
AI Analysis | Feedback
The key risks for Creative Medical Technology (symbol: CELZ) are primarily associated with its status as a clinical-stage biotechnology company developing novel biological therapeutics. These risks are inherent to the industry and include:
-
Clinical Trial and Regulatory Hurdles
As a clinical-stage company, Creative Medical Technology's business success is heavily reliant on the successful progression and completion of its clinical trials and obtaining subsequent regulatory approvals. Failure to meet endpoints in pivotal Phase I/II trials, such as the ADAPT Trial for chronic lower back pain or CREATE-1 for Type 1 Diabetes, would constitute a major setback. While some of its lead programs, like CELZ-201-DDT, have received FDA Fast Track Designation, this does not guarantee eventual approval. The complex and rigorous FDA approval processes for therapies, particularly those involving cell and gene therapy products, represent a constant and significant challenge.
-
Financial Stability and Dilution Risk
Creative Medical Technology is currently in an investment phase, operating with significant net losses and minimal revenue. The company is burning cash to fund its research and development pipeline, reporting a net loss of $4.11 million for the nine months ended September 30, 2025. Although it has managed its liquidity effectively with recent capital raises and a strong current ratio, the company anticipates needing additional capital to support ongoing operations and clinical trials. Future capital raises could lead to the dilution of existing stockholder equity through new offerings. Analysts do not expect the company to reach a breakeven point until at least 2027, highlighting the long and uncertain road to profitability.
-
Market Competition and Early-Stage Pipeline
Creative Medical Technology operates in highly competitive markets for regenerative therapies. Its pipeline, including platforms like AlloStem, ImmCelz, and iPScelz, and specific programs such as CELZ-201-DDT for back pain and CELZ-101 for diabetes, are largely in early development stages. This early stage of development inherently carries significant uncertainty regarding their eventual commercial viability and success. The company faces competition from larger pharmaceutical entities already developing or marketing competing therapies in areas like diabetes and back pain, which could limit the market uptake and commercial potential of Creative Medical Technology's offerings even if they achieve regulatory approval.
AI Analysis | Feedback
The emergence of advanced gene editing technologies, such as CRISPR-Cas9, presents a clear emerging threat. While Creative Medical Technology (CELZ) primarily focuses on developing regenerative medicine using stem cell-based therapies for various conditions including neurological, autoimmune, and metabolic disorders, gene editing platforms offer an alternative, and potentially more precise and durable, therapeutic modality. These technologies can directly modify genes or cells (including immune cells and somatic cells) to correct underlying genetic defects or alter cellular function, potentially offering a different and superior approach to treating diseases that CELZ aims to address with cell transplantation or modulation. As gene editing therapies continue to advance rapidly through clinical trials and gain regulatory approvals for a broadening range of indications, they could disrupt the market for certain traditional cell-based therapies by providing a more fundamental or permanent solution to disease, akin to a paradigm shift in how advanced therapies are delivered.
AI Analysis | Feedback
Creative Medical Technology (CELZ) is a biotechnology company focused on regenerative medicine therapies across various fields, including immunology, endocrinology, urogynecology, and orthopedics. The company's main products and services, along with their addressable market sizes and regions, are as follows:
- ImmCelz® (CELZ-100/CELZ-101) for Type 1 Diabetes: The global Type 1 Diabetes market is estimated at USD 16.97 billion in 2025 and is expected to reach USD 26.22 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2025 to 2032.
- AlloStem™ (CELZ-201) for Type 1 Diabetes: The global Type 1 Diabetes market is estimated at USD 16.97 billion in 2025 and is expected to reach USD 26.22 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2025 to 2032. The U.S. Type 1 Diabetes market size was USD 11.23 billion in 2024 and is anticipated to reach approximately USD 24.27 billion by 2034, with a CAGR of 8%.
- AlloStemSpine (CELZ-201-DDT) for Chronic Lower Back Pain (Degenerative Disc Disease): The global spinal disorders treatment market is projected to exceed USD 20 billion by 2030.
- ImmCelz® for Immuno-Oncology (various indications, including potential solid tumor carcinoma): The global Immuno-Oncology Cell Therapy Market is valued at USD 11.9 billion in 2024 and is predicted to reach USD 95.3 billion by 2034, at a CAGR of 23.2% during the forecast period of 2025-2034. The broader global immuno-oncology (IO) market size was estimated at USD 43.73 billion in 2023 and is projected to reach approximately USD 284.29 billion by 2033.
- ImmCelz® for Stroke Recovery: The global stroke market was valued at USD 33.00 billion in 2024 and is expected to reach USD 58.93 billion by 2032, growing at a CAGR of 7.8% from 2024 to 2032.
- CaverStem™ for Erectile Dysfunction Treatment: The global erectile dysfunction drugs market size was estimated at USD 2.93 billion in 2024 and is predicted to be worth approximately USD 6.74 billion by 2034, expanding at a CAGR of 8.69% from 2025 to 2034. North America dominated this market in 2024.
- FemCelz™ for Female Sexual Function Treatment: null
- iPSCelz (Induced Pluripotent Stem Cell platform): null (currently in pre-clinical stage and early development, broader regenerative medicine market discussed below).
- Alova/OvaStem for Infertility/Premature Ovarian Failure: null
- XoFlo (Exosome enrichment product for musculoskeletal and soft tissue injuries, skin rejuvenation, and scar reduction): null
- Regenerative Medicine Industry (General): The broader regenerative medicine industry is projected to grow to USD 79.23 billion by 2026 globally.
AI Analysis | Feedback
Creative Medical Technology (CELZ) is anticipated to experience significant revenue growth over the next 2-3 years, driven by several key factors as the company transitions from a development-stage to a revenue-generating enterprise. Analysts project the company's revenue to grow at an impressive 67% annually over this period. Here are the expected drivers of future revenue growth for CELZ:- Advancement and Commercialization of Clinical Programs: A primary driver will be the successful progression and potential commercialization of its FDA-cleared clinical programs. Specifically, the CELZ-201-DDT (ADAPT Trial) targeting chronic lower back pain due to degenerative disc disease, an estimated $11 billion annual market, is expected to have topline results in the first half of 2026. Additionally, the CELZ-201 (CREATE-1 Trial) for new-onset Type 1 Diabetes, a global treatment market estimated at $35 billion annually, is anticipated to provide early data in 2026. These programs are identified as "major potential near-term catalysts" targeting "multi-billion-dollar markets."
- Expansion and Application of the ImmCelz Platform: The ImmCelz platform is a core differentiator for the company, possessing "Multi-Billion Dollar Indication Potential." Recent patent acquisitions in Q3 2025 have broadened ImmCelz's coverage to include Type 1 Diabetes and Heart Failure, with patents extending to 2043 and 2042, respectively, thereby securing long-term exclusivity in these high-value markets. This platform, which utilizes a patient's own immune system to initiate regeneration, could unlock revenue streams across various chronic inflammatory and autoimmune conditions.
- Leveraging AI Integration for Accelerated Development: Creative Medical's integration of Artificial Intelligence (AI) into its iPScelz platform is expected to enhance the efficiency and precision of its therapeutic development. This AI-driven approach aims to accelerate target discovery, optimize donor selection, and model in-vivo behavior, ultimately reducing development time and costs. This "Regenerative Medicine 2.0" strategy could lead to a faster pipeline of new products and services, contributing to future revenue growth.
- Monetization of Intellectual Property and Existing Products: With a robust intellectual property portfolio of over 60 patents and pending applications, Creative Medical is positioned to generate revenue through licensing agreements. While current revenue is minimal, the company is a "commercial-stage biotechnology company" that offers products like CaverStem for erectile dysfunction and FemCelz for genital sensitivity and dryness. The successful commercialization and increased market penetration of these existing products, alongside new offerings resulting from its extensive patent portfolio and clinical successes, will contribute to revenue.
AI Analysis | Feedback
Share Repurchases
- On June 12, 2023, Creative Medical Technology Holdings, Inc. authorized a share repurchase program for up to $2 million of its common stock.
- As of December 31, 2024, the company had repurchased 101,250 shares of common stock under this plan for an aggregate purchase price of $445,916.
Share Issuance
- In March 2025, the company raised approximately $3.7 million through warrant exercise inducements.
- In October 2025, Creative Medical Technology Holdings generated approximately $4.2 million in gross proceeds from the immediate exercise of existing warrants and subsequently issued new unregistered warrants to purchase up to 2,790,340 shares of common stock.
- The company completed a registered direct offering and a concurrent private placement in October 2024, which collectively raised approximately $1.6 million through the sale of common stock and warrants.
- The company increased its authorized shares of common stock from 5,000,000 to 25,000,000 as of its December 31, 2024 filing.
Inbound Investments
- Creative Medical Technology Holdings received approximately $3.7 million in March 2025 from warrant exercises by certain holders.
- In October 2025, the company secured approximately $4.2 million in gross proceeds from the immediate exercise of outstanding warrants.
- Approximately $1.6 million was raised in October 2024 through a registered direct offering and a concurrent private placement.
Capital Expenditures
- For the nine-month period ended September 30, 2024, research and development expenses increased to $1,928,937 from $1,621,231 in the prior year, primarily due to increased costs associated with clinical trials.
- As of December 31, 2022, the company believed its cash and certificates of deposit were sufficient to meet anticipated operating costs and capital expenditure requirements through at least March 2024.
- Operating expenses in Q3 2025 included ongoing R&D, partly offset by lower R&D as the AlloStemSpine ADAPT trial progressed through recruitment.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.74 |
| Mkt Cap | 1.4 |
| Rev LTM | 429 |
| Op Inc LTM | -46 |
| FCF LTM | -29 |
| FCF 3Y Avg | -12 |
| CFO LTM | -22 |
| CFO 3Y Avg | -3 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 13.9% |
| Rev Chg Q | 20.8% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | -2.2% |
| Op Mgn 3Y Avg | -4.6% |
| QoQ Delta Op Mgn LTM | -1.3% |
| CFO/Rev LTM | -9.2% |
| CFO/Rev 3Y Avg | -13.2% |
| FCF/Rev LTM | -13.6% |
| FCF/Rev 3Y Avg | -18.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.4 |
| P/S | 6.1 |
| P/EBIT | 6.5 |
| P/E | 8.9 |
| P/CFO | -4.6 |
| Total Yield | -5.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.3% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.7% |
| 3M Rtn | -18.5% |
| 6M Rtn | -10.9% |
| 12M Rtn | -16.9% |
| 3Y Rtn | 7.7% |
| 1M Excs Rtn | -6.2% |
| 3M Excs Rtn | -17.3% |
| 6M Excs Rtn | -21.6% |
| 12M Excs Rtn | -30.7% |
| 3Y Excs Rtn | -51.4% |
Price Behavior
| Market Price | $2.02 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -68.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.23 | $2.71 |
| DMA Trend | down | down |
| Distance from DMA | -9.3% | -25.3% |
| 3M | 1YR | |
| Volatility | 85.7% | 119.1% |
| Downside Capture | 238.60 | 134.22 |
| Upside Capture | -44.30 | 68.64 |
| Correlation (SPY) | 20.2% | 16.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.30 | 1.22 | 1.60 | 2.00 | 0.99 | 0.74 |
| Up Beta | 4.88 | 4.62 | 4.34 | 5.21 | 0.87 | 0.82 |
| Down Beta | 0.29 | -1.13 | 1.16 | 2.18 | 0.97 | 0.88 |
| Up Capture | 126% | 53% | -39% | 14% | 58% | 14% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 11 | 20 | 26 | 67 | 123 | 341 |
| Down Capture | 94% | 310% | 216% | 142% | 123% | 100% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 9 | 20 | 32 | 54 | 116 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CELZ | |
|---|---|---|---|---|
| CELZ | -36.7% | 118.9% | 0.17 | - |
| Sector ETF (XLV) | 7.7% | 17.2% | 0.27 | 8.8% |
| Equity (SPY) | 16.1% | 19.2% | 0.65 | 16.2% |
| Gold (GLD) | 76.5% | 23.4% | 2.38 | 6.6% |
| Commodities (DBC) | 11.1% | 15.9% | 0.48 | 7.2% |
| Real Estate (VNQ) | 5.3% | 16.5% | 0.14 | 15.6% |
| Bitcoin (BTCUSD) | -18.9% | 39.9% | -0.43 | 13.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CELZ | |
|---|---|---|---|---|
| CELZ | -38.0% | 130.5% | 0.10 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 5.6% |
| Equity (SPY) | 14.0% | 17.1% | 0.65 | 10.3% |
| Gold (GLD) | 20.8% | 16.5% | 1.03 | 3.2% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | 3.0% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 7.7% |
| Bitcoin (BTCUSD) | 21.1% | 57.5% | 0.56 | 8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CELZ | |
|---|---|---|---|---|
| CELZ | -11.8% | 6,944.5% | 0.45 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 2.3% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 1.7% |
| Gold (GLD) | 15.6% | 15.3% | 0.85 | -1.9% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | -4.3% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 0.7% |
| Bitcoin (BTCUSD) | 71.5% | 66.4% | 1.11 | -0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.